CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Tapinarof cream, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05186805
NCT05186805Phase 2Completed
CompareCT.gov

Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Organon and Co·interventional·Posted Jan 11, 2022·Updated Sep 5, 2025

In Brief

A Phase 2 clinical trial evaluating Tapinarof cream, 1% for Atopic Dermatitis. Completed, enrolled 36 participants across 10 sites in 2 countries.

Detailed Summary

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 11, 2022
Enrollment StartNov 15, 2021
Primary CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.5 years ago

Interventions

Tapinarof cream, 1%drug

Tapinarof cream, 1% applied topically once daily